Kpv Research
Product image coming soon
KPV: Alpha-MSH Derived Tripeptide and Melanocortin Research
KPV (Lys-Pro-Val) is a synthetic tripeptide derived from the C-terminal of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied in laboratory settings for its role in melanocortin receptor pharmacology and anti-inflammatory signalling pathway research. Despite its small size, KPV has been the subject of substantial research interest due to its activity in inflammatory cell models.
Chemical and Molecular Data
| Property | Value |
|---|---|
| Molecular formula | C16H31N3O4 |
| Molecular weight | 329.43 g/mol |
| CAS number | 1101-61-7 |
| Sequence | Lys-Pro-Val |
| Amino acid count | 3 |
| Parent peptide | Alpha-MSH (C-terminal fragment, positions 11-13) |
| Purity | greater than or equal to 98% as verified by HPLC |
| Form | Lyophilised powder |
| Storage | -20 degrees C, protected from light and moisture |
| Reconstitution | Sterile water recommended |
KPV: Alpha-MSH C-terminal Tripeptide and Melanocortin Pathway
Alpha-MSH and Melanocortin Biology
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13 amino acid neuropeptide derived from pro-opiomelanocortin (POMC) processing. In addition to its well-known role in pigmentation through MC1R, alpha-MSH exerts potent anti-inflammatory effects through melanocortin receptors (MC1R, MC3R, MC5R) expressed on immune cells. The C-terminal KPV tripeptide (residues 11-13 of alpha-MSH) retains significant anti-inflammatory activity in laboratory models despite lacking the full receptor binding pharmacophore of the parent peptide.
Melanocortin Receptor Pharmacology Research
Laboratory research has examined KPV's interactions with melanocortin receptors, particularly MC1R, MC3R, and MC5R expressed on macrophages, monocytes, and other immune cells. Research has investigated whether KPV's anti-inflammatory effects are receptor-mediated or operate through receptor-independent mechanisms.
The melanocortin system and its anti-inflammatory signalling through cAMP/PKA pathways and NFkB suppression has been studied as a context for understanding KPV's mechanism of action in inflammatory models.
Anti-inflammatory Signalling Research
The primary research focus on KPV involves its effects on inflammatory signalling pathways in cell culture models. Laboratory studies have examined:
NFkB pathway modulation. Research has investigated KPV's effects on NFkB nuclear translocation, IkB phosphorylation, and expression of NFkB-dependent inflammatory genes in macrophage and epithelial cell models.
Cytokine regulation. Studies have examined KPV's effects on pro-inflammatory cytokine production (IL-1beta, TNF-alpha, IL-6, IL-8) and anti-inflammatory mediators in stimulated immune cell models.
Intestinal epithelial research. KPV has been studied in intestinal epithelial cell models relevant to mucosal immunology research, with investigations of barrier function and inflammatory signalling in Caco-2 and similar cell systems.
Research Applications
KPV is used in melanocortin receptor pharmacology studies, NFkB pathway anti-inflammatory research, cytokine regulation studies in macrophage models, intestinal epithelial barrier research, and as a minimal active fragment reference compound in alpha-MSH pharmacology studies.
Alpha-MSH Derived Peptides: Research Comparison
| Peptide | Sequence | Length | Receptor activity | Research focus |
|---|---|---|---|---|
| Alpha-MSH | Ac-SYSMEHFRWGKPV-NH2 | 13aa | MC1R, MC3R, MC5R | Broad melanocortin |
| KPV | Lys-Pro-Val | 3aa | Partial MC1/3/5 | Anti-inflammatory signalling |
| [Nle4-D-Phe7]-alpha-MSH | Modified alpha-MSH | 13aa | Full MC1-5 | Pan-melanocortin research |
| MT-II | Ac-Nle-cyc[Asp-His-D-Phe-Arg-Trp-Lys]-OH | 7aa cyclic | Full MC1-5 | SAR studies |
Melanocortin System Overview
The melanocortin system comprises five G-protein coupled receptors (MC1R-MC5R), two endogenous agonists (alpha-MSH, ACTH, and related POMC-derived peptides), and two endogenous antagonists (AgRP and agouti protein). Key features relevant to KPV research:
- MC1R is expressed on melanocytes, macrophages, and dendritic cells. MC1R activation reduces pro-inflammatory cytokine production and increases anti-inflammatory mediators.
- MC3R is expressed in the hypothalamus, immune cells, and gut. Research has examined MC3R's role in energy homeostasis and immune regulation.
- MC5R is expressed on immune cells, exocrine glands, and other tissues. MC5R activation has been studied in the context of immune cell activation and exocrine secretion.
KPV's ability to interact with these receptors despite being only 3 amino acids has made it a useful minimal pharmacophore for studying melanocortin biology in inflammatory research models.
Frequently Asked Questions
Does KPV interact with melanocortin receptors directly or through a different mechanism?
The mechanistic basis of KPV's effects in laboratory models is not fully resolved. Some research suggests KPV can interact with MC1R, MC3R, and MC5R, though with lower affinity than full-length alpha-MSH. Other research has proposed receptor-independent mechanisms involving direct inhibition of NFkB pathway components. In practical terms, most laboratory research uses KPV as a functional tool and characterises downstream pathway changes (NFkB nuclear translocation, cytokine production, calcium signalling) rather than relying on a single defined mechanism.
Why does KPV retain activity despite losing most of the alpha-MSH sequence?
The C-terminal tripeptide Lys-Pro-Val represents the very end of the alpha-MSH sequence. Structure-activity relationship research with alpha-MSH analogues has demonstrated that the C-terminal region contributes to receptor binding, while the central His-Phe-Arg-Trp core is the primary receptor activation pharmacophore. KPV's activity in inflammatory models at concentrations higher than those required for alpha-MSH suggests it acts as a weak partial agonist or modulator rather than a potent receptor agonist, making it useful for studying the concentration-dependent aspects of melanocortin signalling.
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.
Related research peptides: Semax | Kisspeptin-10 | BPC-157
Alpha-MSH Structure-Activity Relationship and KPV
Understanding why KPV retains activity despite losing 10 of alpha-MSH's 13 amino acids requires examining the SAR of the melanocortin system. Systematic truncation studies established that the central His-Phe-Arg-Trp tetrapeptide (positions 6-9 of alpha-MSH) is the minimal receptor-binding pharmacophore for all five MCR subtypes. This core sequence is present in ACTH, all MSH variants, and synthetic melanocortin analogues.
KPV represents the extreme C-terminal end of alpha-MSH — positions 11-13 — which is outside the canonical His-Phe-Arg-Trp pharmacophore. Its retention of biological activity in some inflammatory research models at concentrations higher than those required by alpha-MSH suggests either: (1) weak, partial MCR agonism with very low receptor affinity requiring high concentrations for measurable effects, or (2) receptor-independent mechanisms involving direct interaction with intracellular signalling components.
Published research by Brzoska et al. (Endocrine Reviews, 2008) provided the most comprehensive analysis of KPV alongside alpha-MSH and other related tripeptides, establishing its profile as an anti-inflammatory agent in immune cell models.
NFkB Pathway Research with KPV
The NFkB transcription factor is a master regulator of inflammatory gene expression. In its inactive state, NFkB (typically the p65/p50 heterodimer) is sequestered in the cytoplasm bound to IkB inhibitor proteins. Inflammatory stimuli (LPS, TNF-alpha, IL-1beta) activate IKK (IkB kinase), which phosphorylates IkB proteins, targeting them for ubiquitin-mediated proteasomal degradation. Free NFkB translocates to the nucleus and drives transcription of cytokines, chemokines, and other inflammatory mediators.
Research examining KPV in inflammatory cell models has investigated whether KPV influences any step in this pathway: IKK activity, IkB phosphorylation and degradation kinetics, NFkB nuclear translocation (measured by EMSA, immunofluorescence, or NFkB-luciferase reporter), and downstream cytokine mRNA and protein production. Published data has suggested KPV can reduce NFkB activation in some models, though the precise molecular target within the pathway remains incompletely characterised.
Intestinal Epithelial Biology
KPV research has particularly examined intestinal epithelial biology, where MC1R, MC3R, and MC5R expression on epithelial cells provides receptor targets for melanocortin-mediated anti-inflammatory signalling. Published research using Caco-2 cells (human colorectal adenocarcinoma-derived intestinal epithelial model) has examined KPV's effects on transepithelial electrical resistance (TEER) as a measure of barrier integrity, cytokine secretion (apical and basolateral), and NFkB activation following inflammatory challenge with IL-1beta or LPS.
The intestinal epithelial research context connects KPV to the broader question of how melanocortin signalling in the gut contributes to intestinal immune homeostasis — a research direction that intersects with BPC-157's well-studied gastrointestinal mucosal biology research.
Frequently Asked Questions
How does KPV compare to full-length alpha-MSH for MC1R research?
Full-length alpha-MSH is the preferred compound for MC1R pharmacology research requiring defined receptor activation kinetics and dose-response characterisation. KPV's very low MCR affinity means that dose-response curves require concentrations several orders of magnitude higher than alpha-MSH, and mechanistic attribution to specific MCR subtypes is more difficult. KPV is most useful as a minimal pharmacophore reference compound rather than as a primary MCR agonist tool.
What is the relevance of KPV's tripeptide size to research applications?
KPV's minimal size (three amino acids, MW 329 Da) provides practical research advantages: excellent aqueous solubility, rapid tissue penetration, and simple synthesis enabling isotope-labelled variants for mechanistic studies. Its small size also means it is less likely to have immunogenic properties — an advantage for in vivo research models where immune responses to larger peptide research compounds can confound results.
Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide